NCT00420641 is a Phase 2 clinical trial of GSK372475 in Depressive Disorder, sponsored by GlaxoSmithKline.

Who is sponsoring NCT00420641?

NCT00420641 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00420641?

Interventions in NCT00420641: GSK372475, Paroxetine, Placebo.

What condition does NCT00420641 study?

NCT00420641 studies Depressive Disorder.

Is NCT00420641 still recruiting?

NCT00420641 is currently completed. Last updated 5 February 2018.

Are results published for NCT00420641?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-02-05 · How we verify

NCT00420641

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MDD POC Study GSK372475 Subjects Depressive Disease

Completed Phase 2 Results posted Last updated 5 February 2018

What this trial tests

Phase 2 trial testing GSK372475 in Depressive Disorder in 492 participants. Completed in 15 October 2008.

Timeline

19 December 2006

Primary endpoint
1 June 2008

15 October 2008

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	492
Start date	19 December 2006
Primary completion	1 June 2008
Estimated completion	15 October 2008
Sites	33 locations across France, Italy, Costa Rica, Chile, Germany, Poland, Canada, Bulgaria

Drugs / interventions tested

GSK372475 — full drug profile →
Paroxetine — full drug profile →
Placebo

Conditions studied

Depressive Disorder — all drugs for Depressive Disorder →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 64, any sex, with Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Mean Change From Randomization at the End of the Treatment Phase in the MADRS Total Score Primary · Week 0 (Randomization) and Week 10

The MADRS scale measures the depression level of a participant. The total score was derived by adding the scores of the following 10 items: 1, apparent sadness; 2, reported sadness; 3, inner tension; 4, reduced sleep; 5, reduced appetite; 6, concentration difficulties; 7, lassitude; 8, inability to feel; 9, pessimistic thoughts; 10, suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score is 60; 0, no depression; 60, severely depressed. Randomization value was defined as the assessment value done on Week 0. Change fr

Group	Value	95% CI
Placebo	-16.9	± 9.97
GSK372475	-19.0	± 9.50
Paroxetine	-20.5	± 8.65

Change From Randomization at the End of the Treatment Phase (Week 10) in Bech Scale (6-item of 17-item Hamilton Depression Rating [HAMD-17] Scale) Score Primary · Week 0 (Randomization) and Week 10

The HAMD is a rating instrument for evaluating severity of symptoms of depression, was completed by the participant. The rating instrument used in this study was the 17-item version (HAM-D17). The Bech scale of the HAMD-17 is composed of 6 identified items out of the 17 items rated in HAMD-17 scale. Each item is rated on either a 3-point scale (0 to 2) or a 5-point scale (0 to 4). The following symptoms were rated on a 5-point scale (0-4): depressed mood, feeling of guilt, work and interests, psychomotor retardation, and anxiety (psychic). The following symptom was rated on a 3-point scale (0-

Group	Value	95% CI
Placebo	-6.2	± 4.32
GSK372475	-7.2	± 3.98
Paroxetine	-7.9	± 3.82

Mean Change From Randomization at the End of the Treatment Phase (Week 10) in Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR) Total Score Primary · Week 0 (Randomization) and Week 10

The IDS-CR is a standardized 30-item, clinician rated scale to assess the severity of a participant's depressive symptoms. The items were rated on a 4-point scale of 0-3, where 0 indicated absence of symptom and higher score indicated greater severity of symptom. In order to calculate the total score of IDS-CR, the following procedures were used: either item 11 or 12 were scored; either item 13 or 14 were scored; if both items 11 and 12 (or 13 and 14) were scored, the highest of the items was scored. The total score was obtained by adding the scores of 28 items of the 30 items. Total scores ra

Group	Value	95% CI
Placebo	-22.3	± 14.21
GSK372475	-25.1	± 13.30
Paroxetine	-26.8	± 12.10

Mean Change From Randomization in IDS- Self-Rated Version (SR) Total Score Over Week 10 Secondary · Week 0 (Randomization) up to Week 10

The IDS-SR is a standardized 30-item, participant rated scale to assess the severity of a participant's depressive symptoms. The items were rated on a 4-point scale of 0-3, where 0 indicated absence of symptom and higher score indicated greater severity of symptom. In order to calculate the total score of IDS-SR, the following procedures were used: either item 11 or 12 were scored; either item 13 or 14 were scored; if both items 11 and 12 (or 13 and 14) were scored, the highest of the items was scored. The total score was obtained by adding the scores of 28 items of the 30 items. Total scores

Week 1

Group	Value	95% CI
Placebo	-7.6	± 9.05
GSK372475	-7.6	± 9.15
Paroxetine	-8.6	± 9.96

Week 4

Group	Value	95% CI
Placebo	-16.8	± 12.12
GSK372475	-15.5	± 13.00
Paroxetine	-19.1	± 12.55

Week 10

Group	Value	95% CI
Placebo	-25.6	± 16.27
GSK372475	-26.9	± 14.73
Paroxetine	-30.5	± 13.66

Mean Change From Randomization in the 16-item Quick Inventory of Depressive Symptomatology-Clinician-rated Version (QIDS-CR16) Total Score Over Week 10 Secondary · Week 0 (Randomization) up to Week 10

QIDS-CR16 is a 16-item rating scale of depressive symptoms rated by the clinician. The items were rated on a 4-point scale of 0-3, where 0 indicated absence of symptom and higher score indicated greater severity of symptom. Total score was obtained by adding scores of items of sad mood, interest, energy/fatigue, sleep disturbance, decrease/increase in appetite or weight, concentration/decision making, suicidal ideation and psychomotor agitation/retardation, the highest score on any 1 of the 4 sleep items, highest score on any 1 appetite/weight item and highest score on either of the 2 psychomo

Week 1

Group	Value	95% CI
Placebo	-1.5	± 2.78
GSK372475	-1.8	± 2.76
Paroxetine	-1.8	± 3.65

Week 2

Group	Value	95% CI
Placebo	-3.3	± 3.67
GSK372475	-3.6	± 4.01
Paroxetine	-3.4	± 4.70

Week 3

Group	Value	95% CI
Placebo	-5.0	± 4.27
GSK372475	-4.3	± 4.24
Paroxetine	-5.3	± 4.64

Week 4

Group	Value	95% CI
Placebo	-5.9	± 4.75
GSK372475	-5.0	± 4.20
Paroxetine	-5.9	± 4.61

Week 5

Group	Value	95% CI
Placebo	-6.5	± 4.64
GSK372475	-6.6	± 5.09
Paroxetine	-7.4	± 4.82

Week 6

Group	Value	95% CI
Placebo	-7.3	± 4.88
GSK372475	-7.3	± 5.55
Paroxetine	-8.6	± 4.92

Week 8

Group	Value	95% CI
Placebo	-7.8	± 5.58
GSK372475	-8.8	± 5.07
Paroxetine	-9.4	± 5.03

Week 10

Group	Value	95% CI
Placebo	-8.5	± 5.31
GSK372475	-9.6	± 4.95
Paroxetine	-10.0	± 4.85

Mean Change From Randomization in the 16-item Quick Inventory of Depressive Symptomatology-Self-rated Version (QIDS-SR16) Total Score Over Week 10 Secondary · Week 0 (Randomization) up to Week 10

QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by participant. The items were rated on a 4-point scale of 0-3, where 0 indicated absence of symptom and higher score indicated greater severity of symptom. Total score was obtained by adding scores of the items of sad mood, interest, energy/fatigue, sleep disturbance, decrease/increase in appetite or weight, concentration/decision making, suicidal ideation and psychomotor agitation/retardation, the highest score on any 1 of the 4 sleep items, highest score on any 1 appetite/weight item and highest score on either of the 2 ps

Week 1

Group	Value	95% CI
Placebo	-2.7	± 3.82
GSK372475	-3.1	± 4.00
Paroxetine	-2.9	± 4.16

Week 4

Group	Value	95% CI
Placebo	-6.4	± 5.23
GSK372475	-5.7	± 5.31
Paroxetine	-6.9	± 5.10

Week 10

Group	Value	95% CI
Placebo	-10.0	± 6.73
GSK372475	-10.6	± 5.64
Paroxetine	-11.6	± 5.39

Mean Change From Randomization in the MADRS Item 2 Score (Reported Sadness) Over Week 10 Secondary · Week 0 (Randomization) up to Week 10

The MADRS scale measures the depression level of a participant. The items of the scale include: 1, apparent sadness; 2, reported sadness; 3, inner tension; 4, reduced sleep; 5, reduced appetite; 6, concentration difficulties; 7, lassitude; 8, inability to feel; 9, pessimistic thoughts; 10, suicidal thoughts. The item 2 (Reported Sadness) of MADRS was scored using a scale 7-point scale of 0-6, where 0 indicates absence of symptom and higher score indicates increased severity of symptom. Randomization value was defined as the assessment value done on Week 0. Change from Randomization in total sc

Week 1

Group	Value	95% CI
Placebo	-0.4	± 0.84
GSK372475	-0.5	± 0.95
Paroxetine	-0.4	± 0.97

Week 2

Group	Value	95% CI
Placebo	-0.8	± 1.00
GSK372475	-0.9	± 1.15
Paroxetine	-0.9	± 1.27

Week 3

Group	Value	95% CI
Placebo	-1.3	± 1.26
GSK372475	-1.2	± 1.28
Paroxetine	-1.5	± 1.28

Week 4

Group	Value	95% CI
Placebo	-1.5	± 1.42
GSK372475	-1.4	± 1.23
Paroxetine	-1.6	± 1.34

Week 5

Group	Value	95% CI
Placebo	-1.6	± 1.43
GSK372475	-1.7	± 1.42
Paroxetine	-2.1	± 1.28

Week 6

Group	Value	95% CI
Placebo	-1.9	± 1.56
GSK372475	-2.0	± 1.53
Paroxetine	-2.4	± 1.29

Week 8

Group	Value	95% CI
Placebo	-2.0	± 1.43
GSK372475	-2.4	± 1.33
Paroxetine	-2.6	± 1.34

Week 10

Group	Value	95% CI
Placebo	-2.4	± 1.52
GSK372475	-2.7	± 1.36
Paroxetine	-2.9	± 1.28

Mean Change From Randomization in the IDS-CR Scale Item 5 (Feeling Sad) Over Week 10 Secondary · Week 0 (Randomization) up to Week 10

The IDS-CR is a standardized 30-item, clinician rated scale to assess the severity of a participant's depressive symptoms. The item 5 (Feeling Sad) of IDS-CR was rated on a 4-point scale of 0-3, where 0 indicated absence of symptom and higher score indicated greater severity of symptom. Randomization value was defined as the assessment value done on Week 0. Change from Randomization in score was the difference between IDS-CR Item 5 score at the time points being analyzed (Week 1, 2, 3, 4, 5, 6, 8 and 10) to Randomization.

Week 1

Group	Value	95% CI
Placebo	-0.2	± 0.61
GSK372475	-0.3	± 0.70
Paroxetine	-0.3	± 0.75

Week 2

Group	Value	95% CI
Placebo	-0.5	± 0.72
GSK372475	-0.5	± 0.85
Paroxetine	-0.6	± 0.87

Week 3

Group	Value	95% CI
Placebo	-0.8	± 0.74
GSK372475	-0.8	± 0.91
Paroxetine	-0.9	± 0.82

Week 4

Group	Value	95% CI
Placebo	-0.9	± 0.84
GSK372475	-0.8	± 0.93
Paroxetine	-1.0	± 0.83

Week 5

Group	Value	95% CI
Placebo	-1.0	± 0.84
GSK372475	-1.0	± 1.06
Paroxetine	-1.3	± 0.86

Week 6

Group	Value	95% CI
Placebo	-1.1	± 0.90
GSK372475	-1.2	± 1.12
Paroxetine	-1.5	± 0.87

Week 8

Group	Value	95% CI
Placebo	-1.2	± 0.92
GSK372475	-1.4	± 0.98
Paroxetine	-1.6	± 0.90

Week 10

Group	Value	95% CI
Placebo	-1.3	± 0.95
GSK372475	-1.5	± 0.99
Paroxetine	-1.7	± 0.88

Mean Change From Randomization at the End of the Treatment Phase (Week 10) in the HAMD-17 Total Score Secondary · Week 0 (Randomization) and Week 10

HAMD-17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items of HAMD-17 are rated on a scale 3-point scale of 0-2 or a 5-point scale of 0-4 where 0 is absence of symptom and higher score indicate more severe symptom. Items rated on the 3-point scale include: insomnia early, middle, late; somatic symptoms gastrointestinal and general; genital symptoms; loss of weight; insight. Items rated on 5-point scale include: depressed mood; feelings of guilt; suicide; work and activities; retardation; agitation; anxiety ps

Week 1

Group	Value	95% CI
Placebo	-1.9	± 4.11
GSK372475	-1.9	± 4.16
Paroxetine	-2.3	± 4.36

Week 2

Group	Value	95% CI
Placebo	-4.3	± 4.87
GSK372475	-4.2	± 5.82
Paroxetine	-4.8	± 5.99

Week 3

Group	Value	95% CI
Placebo	-6.6	± 5.66
GSK372475	-4.9	± 6.73
Paroxetine	-6.9	± 6.39

Week 4

Group	Value	95% CI
Placebo	-7.7	± 6.51
GSK372475	-6.3	± 6.30
Paroxetine	-7.9	± 6.43

Week 5

Group	Value	95% CI
Placebo	-8.5	± 6.36
GSK372475	-7.8	± 7.68
Paroxetine	-9.9	± 6.34

Week 6

Group	Value	95% CI
Placebo	-9.9	± 7.08
GSK372475	-9.5	± 8.38
Paroxetine	-11.6	± 6.62

Week 8

Group	Value	95% CI
Placebo	-10.4	± 7.88
GSK372475	-11.5	± 7.78
Paroxetine	-12.7	± 7.02

Week 10

Group	Value	95% CI
Placebo	-11.5	± 7.73
GSK372475	-12.9	± 7.46
Paroxetine	-13.9	± 6.89

Mean Change From Randomization in the HAMD-17 Scale Item 1 (Depressed Mood) Over Week 10 Secondary · Week 0 (Randomization) up to Week 10

HAMD-17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, work and activities, sleep, suicide, psychomotor agitation/retardation, appetite, sexual interest, anxiety, and somatic symptoms). The items of the HAMD-17 are rated on a 3-point scale of 0-2 or a 5-point scale of 0-4. The item 1 (Depressed Mood) of HAMD-17 was rated the 5-point scale of 0-4, where 0 indicates absence of symptom and higher score indicates more severe symptom. Randomization value was defined as the assessment

Week 1

Group	Value	95% CI
Placebo	-0.3	± 0.69
GSK372475	-0.4	± 0.83
Paroxetine	-0.3	± 0.79

Week 2

Group	Value	95% CI
Placebo	-0.6	± 0.84
GSK372475	-0.7	± 1.03
Paroxetine	-0.7	± 0.97

Week 3

Group	Value	95% CI
Placebo	-1.0	± 1.06
GSK372475	-0.9	± 1.12
Paroxetine	-1.0	± 1.01

Week 4

Group	Value	95% CI
Placebo	-1.0	± 1.10
GSK372475	-1.0	± 1.10
Paroxetine	-1.2	± 1.04

Week 5

Group	Value	95% CI
Placebo	-1.2	± 1.11
GSK372475	-1.2	± 1.21
Paroxetine	-1.5	± 1.06

Week 6

Group	Value	95% CI
Placebo	-1.3	± 1.16
GSK372475	-1.5	± 1.31
Paroxetine	-1.7	± 1.03

Week 8

Group	Value	95% CI
Placebo	-1.4	± 1.18
GSK372475	-1.8	± 1.13
Paroxetine	-1.8	± 1.06

Week 10

Group	Value	95% CI
Placebo	-1.7	± 1.24
GSK372475	-2.0	± 1.18
Paroxetine	-2.0	± 1.06

Mean Change From Randomization in IDS-CR and IDS-SR 5 Item Subscale Over Week 10 Secondary · Week 0 (Randomization) up to Week 10

The IDS-CR and IDS-SR is a standardized 30-item scale rated by the clinician and the participant respectively to assess the severity of a participant's depressive symptoms. The 5 items of the IDS subscale include: item 19 (general interest/involvement), item 20 (energy/fatigability), item 21 (pleasure/enjoyment), item 22 (sexual interest), item 30 (Leaden paralysis/physical energy) which assessed participant's pleasure, interest and energy. The items were rated on a 4-point scale of 0-3, where 0 indicated absence of symptom and higher score indicated greater severity of symptom. Total score ra

IDS-CR 5 Item subscale, Week 1

Group	Value	95% CI
Placebo	-0.8	± 2.08
GSK372475	-1.2	± 2.32
Paroxetine	-0.8	± 2.21

IDS-CR 5 Item subscale, Week 2

Group	Value	95% CI
Placebo	-1.6	± 2.49
GSK372475	-2.5	± 2.85
Paroxetine	-2.0	± 2.85

IDS-CR 5 Item subscale, Week 3

Group	Value	95% CI
Placebo	-2.6	± 3.05
GSK372475	-2.9	± 3.13
Paroxetine	-2.9	± 3.12

IDS-CR 5 Item subscale, Week 4

Group	Value	95% CI
Placebo	-3.1	± 3.41
GSK372475	-3.5	± 3.13
Paroxetine	-3.4	± 3.06

IDS-CR 5 Item subscale, Week 5

Group	Value	95% CI
Placebo	-3.8	± 3.24
GSK372475	-4.3	± 3.60
Paroxetine	-4.4	± 3.41

IDS-CR 5 Item subscale, Week 6

Group	Value	95% CI
Placebo	-4.4	± 3.76
GSK372475	-4.8	± 3.81
Paroxetine	-5.2	± 3.59

IDS-CR 5 Item subscale, Week 8

Group	Value	95% CI
Placebo	-4.8	± 3.85
GSK372475	-5.6	± 3.56
Paroxetine	-5.9	± 3.41

IDS-CR 5 Item subscale, Week 10

Group	Value	95% CI
Placebo	-5.3	± 3.73
GSK372475	-6.2	± 3.42
Paroxetine	-6.3	± 3.21

Mean Change From Randomization in the Clinical Global Impression-Severity of Illness (CGI-S) Scale Over Week 10 Secondary · Week 0 (Randomization) up to Week 10

The CGI-S scale measures the severity of psychiatric symptoms on a 7-point scale from 1-7. The scores indicated the following: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. The score ranged from 1-7, where 1 indicated absence of symptoms and higher score indicated greater severity of symptoms. Randomization value was defined as the assessment value done on Week 0. Change from Randomization in the score was the difference between CGI-S score at the individual time po

Week 1

Group	Value	95% CI
Placebo	-0.2	± 0.54
GSK372475	-0.3	± 0.55
Paroxetine	-0.2	± 0.56

Week 2

Group	Value	95% CI
Placebo	-0.5	± 0.70
GSK372475	-0.5	± 0.93
Paroxetine	-0.6	± 0.88

Week 3

Group	Value	95% CI
Placebo	-0.8	± 0.91
GSK372475	-0.7	± 1.09
Paroxetine	-1.1	± 1.19

Week 4

Group	Value	95% CI
Placebo	-1.1	± 1.11
GSK372475	-1.0	± 1.20
Paroxetine	-1.3	± 1.28

Week 5

Group	Value	95% CI
Placebo	-1.2	± 1.23
GSK372475	-1.4	± 1.41
Paroxetine	-1.6	± 1.28

Week 6

Group	Value	95% CI
Placebo	-1.5	± 1.30
GSK372475	-1.6	± 1.54
Paroxetine	-2.0	± 1.36

Week 8

Group	Value	95% CI
Placebo	-1.7	± 1.40
GSK372475	-1.9	± 1.51
Paroxetine	-2.2	± 1.31

Week 10

Group	Value	95% CI
Placebo	-1.9	± 1.41
GSK372475	-2.2	± 1.54
Paroxetine	-2.5	± 1.27

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events were collected up to Follow-up (18 weeks).. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Placebo

Serious: 2/156 (1%)

Deaths: 0/156

GSK372475

Serious: 8/171 (5%)

Deaths: 1/171

Paroxetine

Serious: 3/166 (2%)

Deaths: 0/166

Serious adverse events (13 terms)

Reaction	System	Placebo	GSK372475	Paroxetine
Adjustment disorder with mixed disturbance of emotion and conduct	Psychiatric disorders	—	—	—
Completed suicide	Psychiatric disorders	—	—	—
Depression	Psychiatric disorders	—	—	—
Major depression	Psychiatric disorders	—	—	—
Mania	Psychiatric disorders	—	—	—
Suicidal ideation	Psychiatric disorders	—	—	—
Influenza	Infections and infestations	—	—	—
Salpingitis	Infections and infestations	—	—	—
Haemorrhoidal haemorrhage	Gastrointestinal disorders	—	—	—
Chest pain	General disorders	—	—	—
Cholelithiasis	Hepatobiliary disorders	—	—	—
Intentional overdose	Injury, poisoning and procedural complications	—	—	—
Synovial cyst	Musculoskeletal and connective tissue disorders	—	—	—

Other adverse events (15 terms — click to expand)

Reaction	System	Placebo	GSK372475	Paroxetine
Dry mouth	Gastrointestinal disorders	—	—	—
Headache	Nervous system disorders	—	—	—
Nausea	Gastrointestinal disorders	—	—	—
Somnolence	Nervous system disorders	—	—	—
Dizziness	Nervous system disorders	—	—	—
Insomnia	Psychiatric disorders	—	—	—
Constipation	Gastrointestinal disorders	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—
Tachycardia	Cardiac disorders	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—
Sleep disorder	Psychiatric disorders	—	—	—
Influenza	Infections and infestations	—	—	—
Palpitations	Cardiac disorders	—	—	—
Hyperhidrosis	Skin and subcutaneous tissue disorders	—	—	—
Fatigue	General disorders	—	—	—

Most-reported serious reactions: Adjustment disorder with mixed disturbance of emotion and conduct, Completed suicide, Depression, Major depression, Mania, Suicidal ideation, Influenza, Salpingitis.

Data from ClinicalTrials.gov NCT00420641 adverse events section.

Sponsor's own description

To evaluate the efficacy, safety and tolerability of GSK372475 compared with placebo in the treatment of outpatients subjects with major depressive disorder to exhibit decreased pleasure, interest and energy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry.
Sakurai H, Yonezawa K, Tani H, Mimura M, et al · · 2022 · cited 21× · PMID 35045580 · DOI 10.1055/a-1714-9097

Verify or expand the search:

Other trials of GSK372475

Trials testing the same drug.

NCT00728208 — GSK372475 PK Study in Healthy Volunteers · Phase 1 · completed

Other recruiting trials for Depressive Disorder

Currently open trials in the same condition.

NCT07290153 — Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC · recruiting
NCT07100951 — Comparing Brief Psychoanalytic Couple Therapy and Emotionally Focused Therapy in Reducing Relationship Distress · NA · recruiting
NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT06901739 — Therapeutic Potential of a Synbiotic to Improve Mental Health in Subjects With Obesity. · NA · recruiting
NCT06724666 — Transdiagnostic Internet-delivered Intervention for Adolescents With Anxiety and Depression · NA · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00420641 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 5 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00420641.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT00420641

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (13 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of GSK372475

Other recruiting trials for Depressive Disorder

Other GlaxoSmithKline trials

Verify against primary sources